Crestline Management LP Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Crestline Management LP increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 2,113.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 238,615 shares of the company's stock after purchasing an additional 227,837 shares during the period. Johnson & Johnson makes up 1.1% of Crestline Management LP's holdings, making the stock its 7th biggest holding. Crestline Management LP's holdings in Johnson & Johnson were worth $34,509,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Cutter Capital Management LP acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $20,474,000. Capital Advantage Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $710,000. Cetera Investment Advisers lifted its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. Cetera Investment Advisers now owns 655,985 shares of the company's stock worth $94,869,000 after buying an additional 11,459 shares during the last quarter. Cercano Management LLC boosted its stake in Johnson & Johnson by 40.6% in the fourth quarter. Cercano Management LLC now owns 2,233 shares of the company's stock valued at $323,000 after buying an additional 645 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Johnson & Johnson by 0.3% during the fourth quarter. Bridgeway Capital Management LLC now owns 151,204 shares of the company's stock worth $21,867,000 after acquiring an additional 454 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Bank of America reduced their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Finally, Leerink Partners reduced their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $171.82.

Johnson & Johnson Stock Down 1.1 %

Shares of Johnson & Johnson stock traded down $1.68 during trading hours on Friday, reaching $153.98. The company's stock had a trading volume of 6,519,728 shares, compared to its average volume of 7,886,108. The company has a market capitalization of $370.49 billion, a P/E ratio of 23.15, a P/E/G ratio of 2.56 and a beta of 0.42. The stock's fifty day simple moving average is $158.12 and its two-hundred day simple moving average is $154.44. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is 57.84%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.